A mechanistic study reports that the circadian gene PER2 can reprogram cholesterol synthesis to block oral cancer progression, with potential implications for chronotherapy. The research describes how PER2 activity shapes intracellular cholesterol production and how that biology may interact with simvastatin, a widely used cholesterol-lowering agent. The work suggests that timing and circadian control could modulate the effectiveness of statins in oral squamous cell carcinoma. By connecting a core clock gene to lipid metabolism, the study outlines a potential strategy to improve therapeutic responses beyond dose alone. The authors frame the findings as opening new avenues for designing treatment schedules and combination concepts around circadian regulation.